Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 5/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165718 | 0.79 | TP53 (0.64) | TP53ALOX12NPC1RAB9AKDM4E | |
| SCHEMBL4963197 | 0.79 | TP53 (0.58) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL69665 | 0.77 | ALDH1A1 (0.56) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL1753102 | 0.76 | ALDH1A1 (0.55) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL30707519 | 0.73 | GABRA2 (0.50) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL20027968 | 0.71 | ALDH1A1 (0.57) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL12156479 | 0.71 | GABRA2 (0.47) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL12156478 | 0.71 | ALDH1A1 (0.58) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL12864335 | 0.70 | GABRA2 (0.46) | GABRA2GABRB2TP53ALOX12NPC1 | |
| SCHEMBL20027601 | 0.69 | ALDH1A1 (0.55) | GABRA2GABRB2TP53ALOX12NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| WO-2008107418-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GRM1, GRM2, GRM3 | GABRA2 74/4885GABRB2 76/4885TP53 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.